Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) for the treatment of adults with locally advanced ...

The combination of brain radiotherapy and chemoimmunotherapy “resulted in promising intracranial and systemic anti-tumor activity, with a manageable safety profile,” researchers wrote.

Novocure today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival ...

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...

Experts shared diagnosis and management strategies for chronic pruritus at the Dermatology Days of Paris 2024 conference.

Learn about rheumatoid vasculitis, neutrophilic dermatoses, and other rheumatoid arthritis rashes, their symptoms, and when ...

A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...

NDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has ...